ELYMUCO Trademark

Trademark Overview

On Monday, November 25, 2019, a trademark application was filed for ELYMUCO with the United States Patent and Trademark Office. The USPTO has given the ELYMUCO trademark a serial number of 88705126. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 12, 2024. This trademark is owned by Galera Therapeutics, Inc.. The ELYMUCO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for reducing side effects and improving efficacy in treatments for cancer and oncology patients; pharmaceuticals for the prevention, treatment and management of superoxide mediated conditions; biotechnological preparations for medical use being biological preparations for the treatment of cancer, oncological disorders and diseases, neurological disorders and diseases, respiratory disorders and diseases, dermatological disorders and diseases, pulmonary disorders and diseases, degenerative disorders and diseases, immunological disorders and diseases, infectious disorders and diseases, cardiovascular disorders and diseases, and radiation protection
elymuco

General Information

Serial Number88705126
Word MarkELYMUCO
Filing DateMonday, November 25, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 17, 2020

Trademark Statements

Goods and ServicesPharmaceuticals for reducing side effects and improving efficacy in treatments for cancer and oncology patients; pharmaceuticals for the prevention, treatment and management of superoxide mediated conditions; biotechnological preparations for medical use being biological preparations for the treatment of cancer, oncological disorders and diseases, neurological disorders and diseases, respiratory disorders and diseases, dermatological disorders and diseases, pulmonary disorders and diseases, degenerative disorders and diseases, immunological disorders and diseases, infectious disorders and diseases, cardiovascular disorders and diseases, and radiation protection

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 3, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGalera Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355
Party NameGalera Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMalvern, PA 19355

Trademark Events

Event DateEvent Description
Tuesday, December 3, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 28, 2019NEW APPLICATION ENTERED
Friday, February 28, 2020ASSIGNED TO EXAMINER
Monday, March 2, 2020NON-FINAL ACTION WRITTEN
Monday, March 2, 2020NON-FINAL ACTION E-MAILED
Monday, March 2, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 23, 2020ASSIGNED TO EXAMINER
Thursday, August 27, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 1, 2020ASSIGNED TO LIE
Thursday, October 1, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 1, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 15, 2020EXAMINERS AMENDMENT -WRITTEN
Thursday, October 15, 2020EXAMINERS AMENDMENT E-MAILED
Thursday, October 15, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, October 15, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 28, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 17, 2020PUBLISHED FOR OPPOSITION
Tuesday, November 17, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 12, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, May 26, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, May 26, 2021SOU EXTENSION 1 FILED
Wednesday, May 26, 2021SOU EXTENSION 1 GRANTED
Friday, May 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 10, 2022SOU TEAS EXTENSION RECEIVED
Monday, January 10, 2022SOU EXTENSION 2 FILED
Monday, January 10, 2022SOU EXTENSION 2 GRANTED
Wednesday, January 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 30, 2022SOU TEAS EXTENSION RECEIVED
Thursday, June 30, 2022SOU EXTENSION 3 FILED
Thursday, June 30, 2022SOU EXTENSION 3 GRANTED
Saturday, July 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 30, 2022SOU TEAS EXTENSION RECEIVED
Friday, December 30, 2022SOU EXTENSION 4 FILED
Friday, December 30, 2022SOU EXTENSION 4 GRANTED
Tuesday, January 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 26, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 26, 2023SOU EXTENSION 5 FILED
Wednesday, July 12, 2023SOU EXTENSION 5 GRANTED
Monday, February 12, 2024ABANDONMENT - NO USE STATEMENT FILED
Thursday, July 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

elymuco disorders diseases cancer pharmaceuticals treatment preparations neurological oncological biological respiratory